论文部分内容阅读
目的:利用溶瘤腺病毒CNHK500体外转染内皮祖细胞,评估其在体外对肺腺癌细胞的特异性杀伤作用。方法:通过溶瘤腺病毒CNHK500转染内皮祖细胞,构建携带CNHK500的内皮祖细胞,并将内皮祖细胞和CNHK500分为三组,即CNHK500组,转染CNHK500的内皮祖细胞组和内皮祖细胞组,分别感染肺腺腺癌细胞A549,用MTT法检测不同肺腺癌细胞A549的生长抑制情况。结果:成功的分离并培养、鉴定内皮祖细胞,并完成CNHK500对内皮祖细胞的转染,CNHK500滴度为2.0×107 pfu/m L,其中CNHK500组肺腺癌细胞A549的存活率为(75.54±5.46)%,转染CNHK500的EPCs组肺腺癌细胞A549的存活率为(80.81±3.69)%,EPCs组肺腺癌细胞A549的存活率为(98.13±2.98)%。结论:本实验首次成功的将CNHK500转染内皮祖细胞,并应用于肺腺癌细胞的生长抑制中,这将有助于为肺腺癌的生物治疗提供一个崭新的策略。
OBJECTIVE: To use in vitro transfection of endothelial progenitor cells with oncolytic adenovirus CNHK500 to evaluate its specific killing effect on lung adenocarcinoma cells in vitro. Methods: Endothelial progenitor cells were transfected with oncolytic adenovirus CNHK500 to construct endothelial progenitor cells carrying CNHK500. Endothelial progenitor cells and CNHK500 were divided into three groups: CNHK500 group, EPCs transfected with CNHK500 and endothelial progenitor cells Group were infected with lung adenocarcinoma A549 cells, MTT assay of different lung adenocarcinoma A549 cell growth inhibition. Results: Endothelial progenitor cells were successfully isolated and cultured. CNHK500 was transfected into endothelial progenitor cells. The titer of CNHK500 was 2.0 × 107 pfu / mL. The survival rate of lung adenocarcinoma A549 cells in CNHK500 group was (75.54) ± 5.46)%. The survival rate of lung adenocarcinoma A549 cells transfected with CNHK500 EPCs was (80.81 ± 3.69)%, and that of EPCs lung adenocarcinoma cells A549 cells was (98.13 ± 2.98)%. CONCLUSION: In this study, we successfully transfected CNHK500 into endothelial progenitor cells for the first time and applied it to the growth inhibition of lung adenocarcinoma cells, which will help to provide a brand new strategy for the biological treatment of lung adenocarcinoma.